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location, salary, race, marital status, full-time/part-time status,
prior comorbidity index, prior medical costs related to BPD,
prior other medical costs, index date, and medical services
related to BPD). Treatment groups were compared over a follow-
up period ranging from 12 to 24 months after the index pre-
scription date. RESULTS: Six hundred ninety-nine patients with
BPD were classiﬁed into the ATYP (n = 25), BOTH (n = 190),
NONE (n = 170), and OTHER (n = 314) treatment groups. The
ATYP group demonstrated the lowest rate of employment ter-
mination (1.5%; 95% CI -3.3%, 6.3%) followed by the BOTH
(5.8%; 95% CI 2.5%, 9.1%), NONE (8.9; 95% CI 4.7%,
13.2%), and OTHER (9.3%; 95% CI 6.1%, 12.5%) groups.
Differences between treatment groups were not signiﬁcant. The
numerical difference between ATYP and OTHER did not reach
signiﬁcance (p = 0.058). CONCLUSIONS: The ATYP group
demonstrated the lowest employment termination rate in the
follow-up period of 12 to 24 months after the index prescription
date. Further research is warranted to examine the inﬂuence of
speciﬁc patient variables and treatment regimens on employment
termination in patients with BPD.
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OBJECTIVES: Compare total and mental health-related costs
among patients with bipolar disorder (BPD) initiated on queti-
apine versus other antipsychotics in a state Medicaid system.
Economic evaluations comparing quetiapine with other antipsy-
chotics are lacking in the published literature. METHODS:
Retrospective study using “de-identiﬁed” Medicaid claims data
of patients with BPD. Patients assigned to quetiapine (QTP),
olanzapine (OLZ), risperidone (RIS), or typical antipsychotic
groups based on ﬁrst prescription ﬁlled between January 1, 1999
and December 31, 2001. Total and mental health-related costs
(including study drug charges) from 12 months before until 12
months after treatment initiation were analyzed, controlling for
various confounders including patient demographics, comor-
bidities, and prior health care utilization. Total health care costs
included costs associated with medical and mental conditions.
Mental health-related costs were identiﬁed by claims associated
with a mental health disorder (ICD-9-CM codes
290.XX–316.XX) or CPT codes for psychiatric services
(90801–90899) and psychiatric medications. RESULTS: A total
of 825 patients with BPD were classiﬁed into OLZ (n = 283,
34.30%), RIS (n = 231, 28.00%), QTP (n = 106, 12.85%), and
typical antipsychotic (n = 205, 24.85%) cohorts. Mean (±SD)
total health care costs over the 12-month follow-up period were
US$15,866 ± US$23,164 (OLZ), US$17,539 ± US$17,570 (RIS),
US$13,227 ± US$18,862 (QTP), and US$17,570 ± US$23,842
(typical antipsychotics). Mean mental health-related costs over
the 12-month follow-up period were US$10,203 ± US$17203
(OLZ), US$9475 ± US$14202 (RIS), US$8064 ± US$7368
(QTP), and US$7,368 ± US$11,239 (typical antipsychotics).
Adjustment for confounders using multivariate analysis revealed
no signiﬁcant differences in total and mental health-related costs
between the QTP group and the other atypical antipsychotic
groups (OLZ, RIS). For the typical antipsychotic group, there
was greater total (28.4%) and mental health-related (8.7%) costs
compared with the QTP group. CONCLUSIONS: There were
no signiﬁcant differences in total and mental health-related costs
between atypical antipsychotic groups. However, patients with
BPD treated with QTP incurred lower total and mental 
health-related costs compared with those receiving typical
antipsychotics.
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OBJECTIVE: To describe the demographic and clinical charac-
teristics of Texas Medicaid enrollees prescribed AP therapy.
METHODS: This was a retrospective database analysis using
electronic medical records from 1997 to 2001 for adults receiv-
ing AP monotherapy who were continuously enrolled in Texas
Medicaid for at least 18 months. Patients were stratiﬁed accord-
ing to a hierarchy of mutually exclusive primary mental health
(PMH) categories for which AP therapy was presumed to be 
prescribed. RESULTS: Data were available for 19,430 patients.
The population was mainly female (65.7%), white (55.1%) and
older (mean age 60.3 years (SD: 21.9), with 47.6% ≥65 years).
PMH diagnoses were: schizophrenia 16.5%; bipolar disorder
15.5%; dementia 14.3%; psychosis 8.1%; non-psychotic disor-
der 14.5%; no mental health diagnosis 31.1%; with 32.1% of
patients having more than one mental health diagnosis. The per-
centages of index AP therapy were: ﬁrst-generation agent 29.3%;
clozapine 0.5%; olanzapine 21.6%; quetiapine 6.3%; risperi-
done 42.2%. This differed when stratiﬁed by age (c2 = 416.748,
df = 16, p < 0.001), gender (c2 = 76.901, df = 4, p < 0.001),
race/ethnicity (c2 = 160.710, df = 12, p < 0.001) and PMH diag-
nosis (c2 = 845.046, df = 20, p < 0.001). Risperidone use was
more common in those ≥65 years (48.3%), females (43.5%),
Hispanics (46.7%), and for dementia patients (50.1%). Olanza-
pine was primarily used in patients aged 45–54 years (33.6%);
males (31.6%); blacks (35.4%), and for schizophrenia (36.5%).
The mean daily dose of the second-generation antipsychotics
(SGAs) differed by age (p < 0.001) and treatment indication 
(p < 0.001). Regardless of the SGA, patients aged ≥65 years
received doses 43.4–51.2% lower than patients aged < 65 years.
Regardless of age, doses for schizophrenia were 26–46% higher
than for bipolar disorder and 60–70% higher than for dementia
patients. CONCLUSIONS: AP agents are prescribed for a
diverse range of indications with signiﬁcant differences in AP
dose according to treatment indication and patient age.
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OBJECTIVE: We compared factors associated with antidepres-
sant treatment selection for patients initiating on duloxetine
versus venlafaxine XR, bupropion, and SSRIs. We tested differ-
ences in subgroups with and without depression diagnoses.
METHODS:Claims from ﬁve US managed care health plans were
obtained for adult patients initiating on new prescriptions for
select antidepressants between August 31, 2004 to December 31,
2004. Diagnostic and treatment history were established through
prior claims (12 months before index medication date).
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RESULTS: Of the 230,738 eligible patients, 29.7% had depres-
sion diagnoses (n = 68,526), 71.4% were female, mean age was
44.6 years, and 77.9% initiated on SSRIs. Using logistic regres-
sion models for the depression cohort, patients initiating on
duloxetine (n = 2061) versus all other initiators were associated
with being older (OR 1.02), having more prior pain diagnoses
(OR 1.11), depression-related diagnoses (OR 1.52), major depres-
sive disorder recurrent episode diagnoses (OR 1.28), pain 
medications (OR 1.27), antidepressants (OR 1.46), and any psy-
chotherapy (OR 1.14) (all p < 0.01). Duloxetine patients also
were more likely to initiate therapy later in the study (OR 1.04;
p < 0.0001) and were prescribed therapy by mental health (OR
2.32) and other specialists (OR 1.40) versus primary care. When
depressive diagnoses were absent, duloxetine patients (n = 2346)
were more likely to be female (OR 1.21; p < 0.001) versus other
antidepressant initiators (n = 162,212). All other factors remained
consistent. Trends over time are necessary to determine the
robustness of results. CONCLUSIONS: In the ﬁrst four months
after the drug’s availability, duloxetine initiators were associated
with worse prior diagnostic and treatment histories. Case mix 
differences should be made when comparing drug cohorts.
MENTAL HEALTH—Methods and Concepts
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OBJECTIVE: To compare the treatment costs of schizophrenia
patients who relapsed in the European SOHO study with those
who never relapsed over three years. METHODS: The SOHO
study is a 3-year perspective, outpatient observational study of
10,972 patients across 10 European countries. The Clinical
Global Impression (CGI) Scale was used to measure clinical
effectiveness on a scale of 1 (not ill) to 7 (most severely ill). The
deﬁnition of relapse was based on increases in the CGI Scale
and/or inpatient admission. Kaplan-Meier analysis was used to
estimate the relapse rate over three years. The resource use (inpa-
tient, day care, psychiatrist visits and medications) for those who
ever relapsed during the three years of study was compared to
those who never relapsed. UK costs were applied to the resource
use. RESULT: A totla of 6397 patients with complete data on
CGI and resources were used in the analysis. A totla of 2489
(39%) patients relapsed over the 3 years. The total cost for
patients who relapsed (16,724.27 pounds) was higher than those
who did not relapse (7724.93 pounds). 6368.88 pounds (71%)
of cost difference was due to inpatient stays, 2020.13 pounds
was due to day-care, 416.11 pounds due to medications and
194.22 pounds due to psychiatrist visits. The costs will also be
modelled adjusting for patient characteristics and taking account
of the fact that the cost data is not normally distributed. 
CONCLUSION: Relapsed patients used more health care
resources in the treatment for schizophrenia. The cost of antipsy-
chotic treatments which prevent relapse could be offset by the
savings associated with preventing relapse.
PMH36
VARIATIONS IN THE OPERATIONAL DEFINITION OF MOOD
DISORDERS IN RETROSPECTIVE CLAIMS DATABASE STUDIES
Montejano LB
Thomson Medstat, Washington, DC, USA
OBJECTIVES: In retrospective claims database studies, deﬁning
the sample often receives less attention than the statistical
methods used in the analysis. However, identifying an appropri-
ate sample is a key step in the analytic process. The current
research was undertaken to identify typical sample selection def-
initions in retrospective claims database studies of mood disor-
ders. METHODS: A PubMed literature search was conducted to
identify January 2000 to September 2005 publications with the
major topic heading of mood disorders and terms such as admin-
istrative data, insurance claims or claims analysis. The criteria
used for sample selection was abstracted from relevant studies.
RESULTS: Forty-seven studies were abstracted, including 10
speciﬁcally focusing on major depressive disorder (MDD), 15 on
depression and 13 on bipolar disorder (BPD). No set of ICD-9-
CM diagnosis codes was used to identify these conditions across
studies. Three studies deﬁned MDD as 296.2 or 293.3 only,
while others included codes for dysthymia (300.4) and depres-
sive disorder not otherwise speciﬁed (311). Some used codes for
adjustment reaction with depressive symptoms (309.0, 309.2).
One study of depression used only 296.2 and 296.3, while
another used nine different 4-digit ICD-9 codes. All BPD studies
that speciﬁed codes used 296.4–296.6, but the inclusion of other
296 codes varied by study. Several publications did not list the
speciﬁc diagnosis codes used. Some studies required at least two
diagnoses, while others required only one. About half the studies
provided little basis for the coding criteria used. CONCLU-
SIONS: A speciﬁc operational deﬁnition of mood disorders was
not evident from the literature. Results of retrospective claims
database studies with different sample selection criteria may
vary, so it is important to assess ﬁndings in light of the sample
deﬁnition.
MENTAL HEALTH—Patient Reported Outcomes
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OBJECTIVES: Compare adherence and persistence among
patients with bipolar disorder (BPD) initiated on quetiapine
versus other antipsychotics in a state Medicaid system over a 12-
month follow-up period. There are few published economic eval-
uations of quetiapine in comparison with other antipsychotics.
METHODS: Claims data for patients with BPD from a “de-
identiﬁed” Medicaid database. Patients were assigned to queti-
apine (QTP), olanzapine (OLZ), risperidone (RIS), or typical
antipsychotic treatment groups based on ﬁrst prescription ﬁlled
between January 1, 1999 and December 31, 2001. Adherence
was measured using the medication possession ratio (MPR):
days’ supply of antipsychotic divided by the number of days
between prescription ﬁlls. Persistence was deﬁned as total
number of days from initiation of treatment to therapy modiﬁ-
cation (discontinuation, switching, or combination with another
antipsychotic). Adjustment for confounders was undertaken
using ordinary least squares (OLS) and Cox proportional hazard
regression modeling. RESULTS: Mean (±SD) MPRs were 0.71 ±
0.25 for QTP (n = 106), 0.68 ± 0.29 for OLZ (n = 283), 0.68 ±
0.27 for RIS (n = 231), and 0.46 ± 0.34 for typical antipsychotics
(n = 205). Patients initiated on typical antipsychotics were
24.4% less adherent than patients initiated on QTP (p < 0.001).
